Integra Lifesciences Holdings Corp (NASDAQ:IART) has been assigned an average recommendation of “Hold” from the fifteen research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $51.00.

A number of research analysts have weighed in on IART shares. Zacks Investment Research upgraded shares of Integra Lifesciences from a “hold” rating to a “buy” rating and set a $57.00 price objective for the company in a research report on Tuesday, October 3rd. Oppenheimer set a $58.00 price objective on shares of Integra Lifesciences and gave the stock a “buy” rating in a research report on Tuesday, December 12th. TheStreet downgraded shares of Integra Lifesciences from a “b” rating to a “c+” rating in a research report on Thursday, October 26th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $52.00 price objective on shares of Integra Lifesciences in a research report on Friday, January 5th. Finally, Bank of America downgraded shares of Integra Lifesciences from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 2nd.

Integra Lifesciences (NASDAQ:IART) traded up $1.30 during trading hours on Monday, reaching $50.47. 483,085 shares of the company’s stock traded hands, compared to its average volume of 718,286. Integra Lifesciences has a one year low of $40.51 and a one year high of $56.42. The company has a debt-to-equity ratio of 1.26, a quick ratio of 3.39 and a current ratio of 4.49. The stock has a market capitalization of $3,950.00, a price-to-earnings ratio of 82.74, a price-to-earnings-growth ratio of 1.55 and a beta of 0.65.

Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings data on Thursday, October 26th. The life sciences company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.02). The firm had revenue of $278.83 million during the quarter, compared to analyst estimates of $286.00 million. Integra Lifesciences had a return on equity of 16.35% and a net margin of 4.52%. The company’s revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the company posted $0.93 EPS. research analysts predict that Integra Lifesciences will post 1.85 EPS for the current year.

In related news, VP Richard D. Gorelick sold 1,500 shares of the company’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total transaction of $70,785.00. Following the completion of the transaction, the vice president now owns 21,665 shares in the company, valued at approximately $1,022,371.35. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Barbara B. Hill acquired 10,768 shares of the business’s stock in a transaction on Tuesday, October 31st. The stock was acquired at an average price of $46.66 per share, with a total value of $502,434.88. Following the acquisition, the director now owns 55,540 shares in the company, valued at approximately $2,591,496.40. The disclosure for this purchase can be found here. 21.50% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. GSA Capital Partners LLP raised its holdings in Integra Lifesciences by 213.1% in the 3rd quarter. GSA Capital Partners LLP now owns 28,249 shares of the life sciences company’s stock valued at $1,426,000 after acquiring an additional 19,226 shares during the last quarter. California Public Employees Retirement System raised its holdings in Integra Lifesciences by 6.8% in the 3rd quarter. California Public Employees Retirement System now owns 132,002 shares of the life sciences company’s stock valued at $6,663,000 after acquiring an additional 8,402 shares during the last quarter. Zions Bancorporation acquired a new stake in Integra Lifesciences in the 3rd quarter valued at about $205,000. Orbimed Advisors LLC raised its holdings in Integra Lifesciences by 155.5% in the 3rd quarter. Orbimed Advisors LLC now owns 1,090,910 shares of the life sciences company’s stock valued at $55,069,000 after acquiring an additional 664,000 shares during the last quarter. Finally, Segall Bryant & Hamill LLC raised its holdings in Integra Lifesciences by 20.9% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 112,520 shares of the life sciences company’s stock valued at $5,680,000 after acquiring an additional 19,486 shares during the last quarter. Institutional investors own 87.58% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/integra-lifesciences-holdings-corp-iart-receives-51-88-average-target-price-from-analysts/1803399.html.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.